Patients with DEPDC5 mutations [12], associated with mTOR pathway dysregulation, may benefit from targeted treatments such as mTOR inhibitors (e.g., everolimus), which have shown promise in related epilepsy syndromes. This evidence concerns the gene MTOR and epilepsy syndrome.